Skip to main content
. 2022 Mar 16;13:1379. doi: 10.1038/s41467-022-28517-z

Fig. 1. Anti-S RBD antibody concentration stratified by biologic therapy (infliximab vs vedolizumab), type of vaccine, vaccine dose and history of prior SARS-CoV-2 infection.

Fig. 1

The wider bar represents the geometric mean, while the narrower bars are drawn one geometric standard deviation on either side of the geometric mean. Based on published data using neutralisation assays threshold shown of 15 U/mL was used to determine seroconversion11. The biologic treatment infliximab is shown in green and vedolizumab in orange. The number of individuals tested for each group are shown in black at the top of each panel. Source data are provided as a Source Data file.